In addition, clinical trials have identified a series of adverse events (AEs) caused by EGFR-TKIs, in which acneiform eruption is the most frequently reported.5–7 In recent years, Shi et al and Qi et al8,9 accomplished meta-analyses to identify the risk of interstitial lung disease with EGFR-TKIs in advanced NSCLC, and another group finished a pooled analysis to determine the incidence and RRs of fatal AEs in cancer patients treated with EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.